Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion type Assertion NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_head.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion description "[The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion evidence source_evidence_literature NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion SIO_000772 25524798 NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion wasDerivedFrom befree-2016 NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.
- NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_assertion wasGeneratedBy ECO_0000203 NP1249521.RAU2bKkhXLQ17mDNQF9TzAspXq8NwL2_kRmqeytMYqLoY130_provenance.